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effect (3.2, 2.5-4.2) respectively. The SI score for interaction was 3.6 (95% CI: 3.1-4.2).
Conclusions: Our study demonstrates that a familial propensity to SCA interacts with
presence of increasing metabolic RF, magnifying the risks for those exposed to both.
1028-168 Is Asymmetric Dimethylarginine a Marker for Diabetes, 
Coronary Artery Disease, and Death/Myocardial 
Infarction? Results of the Intermountain Heart 
Collaborative Angiographic Registry Study
Jeffrey L. Anderson, John F. Carlquist, William L. Roberts, Benjamin D. Horne, Tami L. 
Bair, Elisabeth L. Schwarz, Marzia Pasquali, Joseph B. Muhlestein, LDS Hospital, Salt 
Lake City, UT, University of Utah, Salt Lake City, UT
Background: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric
oxide synthase that has generated interest as a potential cause or marker of endothelial
dysfunction and its clinical consequences, including diabetes, coronary artery disease
(CAD), and renal failure.
Methods: We tested whether ADMA distinguishes patients (pt) with normal (NFG; <110
mg/dL), or impaired fasting glucose (IFG; 110-125), and diabetes (DM; >126 mg/dL);
angiographic CAD; and death (D) or nonfatal myocardial infarction (MI) in a case-control
cohort of 442 pt selected from the 3 glycemic categories from among 3000 pt entered in
the Intermountain Heart Collaborative Registry. Consenting pt had fasting blood drawn
for FG and ADMA during angiographic assessment and were followed for 2.6 ± 1.4 y.
ADMA was assayed from cryogenically stored samples by high-pressure liquid chroma-
tography with pre-column derivitzation and fluorescence detection. Non-parametric (KW)
testing compared ADMA among groups. Logistic regression was used for predictive mod-
eling.
Results: The study cohort consisted of equal numbers with NFG (146), IFG (148), and
DM (148), matched for age (±5 y) and gender. Overall, age averaged 61 years; 72% were
male; 24%, smokers; 68% had angiographic CAD; 61%, hypertension; 58%, hyperlipi-
demia; 24%, prior MI. During follow-up, 137 events occurred. Distribution of ADMA was
broad and rightward skewed, with median 0.85 µM (range, 0-30). Mean (median) ADMA
levels increased progressively by glycemic category (p<0.001): NFG=2.3 (0.74), IFG=3.0
(0.77), DM= 3.4 (1.27). When adjusted for standard risk factors, CAD severity, and pre-
senting diagnosis, ln ADMA independently predicted DM (odds ratio [OR] 1.29 /ln unit, CI
1.07-1.54, p=0.006) and, less strongly, CAD (OR 1.21, CI 1.0-1.5, p=0.06). Ln ADMA
trended higher in those with D/MI (adjusted OR 1.17, CI 0.98-1.39, p=0.08).
Discussion: Among a high coronary risk case-control cohort, ↑ADMA predicted ↑risk of
IFG, DM, and CAD. Thus, ADMA might contribute to endothelial dysfunction associated
with these conditions. Further research should determine whether ADMA is a causal fac-
tor or passive marker and determine causes of interpatient variability.
1028-169 The Predictive Value of Parental History of Coronary 
Disease
Pamela Ouyang, Lisa R. Yanek, Daniele Fallin, Taryn F. Moy, Lewis C. Becker, Diane M. 
Becker, Johns Hopkins University School of Medicine, Baltimore, MD, Johns Hopkins 
University Bloomberg School of Public Health, Baltimore, MD
Background: Parental history of coronary disease (CHD) is a well-known risk factor for
CHD. However the risk conferred by the gender of an affected parent is controversial and
data are sparse. This prospective study in high risk families was designed to determine
the extent to which a maternal or paternal history of CHD contributed independently to
the risk of incident CHD after adjusting for known risk factors.
Methods: Unaffected siblings (SIBS) of probands were identified from hospitalized index
cases with a documented CHD event < 60 years of age. This prospective analysis
includes 345 women and 339 men with either maternal, paternal or no parent with history
of CHD. Parental family history was elicited by self-report and confirmed by another fam-
ily member. SIBS were followed for incident CHD events. SIB events were documented
by medical records and adjudicated by an external endpoints committee.
Results: The 684 SIBS were 46±7 yrs old at baseline, 50% female, 21% African Ameri-
can, 32% smokers, 7% diabetics, 43% hypertensives, and 67% hypercholesterolemic.
Incident CHD occurred in 84/684 (12.3%) of all SIBS over 8.7±3.2 yrs follow-up. Incident
events occurred in 12.9% of SIBS with no parental history, 10.5%; of sibs with a paternal
history only, and 14.8% of SIBS with a maternal CHD history only. In a Cox proportional
hazard analysis predicting incident CHD in SIBS, the multivariate adjusted relative risk for
maternal CHD was 2.05 (95% CI=1.15-3.65) and for paternal history was 1.0 (95%
CI=0.6-1.66), controlling for age, SIB sex, race, hypertension, current smoking, LDL cho-
lesterol, diabetes, obesity and education.
Conclusion: Among individuals with a documented family history of premature CHD,
having a maternal history of CHD was most strongly associated with the highest risk of a
CHD event. Controlling for known risk factors, maternal history alone conferred a signifi-
cant and independent excess risk of incident CHD whereas paternal alone history was
not significant.
1028-170 Higher Levels of Lipoprotein-Associated Phospholipase 
A2 Are Associated With Higher Incidence of 
Cardiovascular Events at Follow-Up Independent of C-
Reactive Protein
Emmanouil S. Brilakis, Joseph P. McConnell, Jr., Ryan J. Lennon, Ahmad A. Elesber, 
Jeffrey G. Meyers, Peter B. Berger, Mayo Clinic, Rochester, MN
Background: Limited data exist on the association between lipoprotein-associated phos-
pholipase A2 (Lp-PLA2) with cardiovascular risk.
Methods and Results: We measured Lp-PLA2 levels in 504 consecutive patients under-
going clinically indicated coronary angiography. Mean age was 60±11 years and 38%
were women. The mean (± SD) Lp-PLA2 level (ng/mL) was 245 ± 91. Median C-reactive
protein (CRP, mg/L) was 0.29 (interquartile range: 0.12, 0.67). During a median follow-up
of 4.0 years, 58 cardiovascular events occurred in 49 of 466 contacted patients (11%):
cardiac death in 6, acute myocardial infarction (AMI) in 14, coronary revascularization in
28, and stroke in 10. Higher Lp-PLA2 levels were associated with a greater risk of cardio-
vascular events: the hazard ratio (HR) per standard deviation was 1.31 (p=0.010), and
remained significant after adjusting for clinical (age, gender, smoking, hypertension) and
lipid (total and HDL cholesterol, Lp(a), and triglycerides) variables and CRP (Table).
Conclusion: Higher Lp-PLA2 levels were associated with a higher incidence of cardio-
vascular events at follow-up, independently of traditional coronary artery disease risk fac-
tors and CRP.
1028-171 Fasting Blood Glucose: An Underestimated Risk Factor 
for Subclinical Coronary Atherosclerosis
Khurram Nasir, Roger S. Blumenthal, Joel B. Braunstein, Romeu Meneghello, Jose A. 
Maluf, Wendy S. Post, Matthew J. Budoff, Raul D. Santos, Johns Hopkins Medical 
Institutions, Baltimore, MD, Albert Einstein Hospital, Sao Paulo, Brazil
Background: Non-diabetic individuals with high fasting blood glucose (FBG) are at high
risk for experiencing the metabolic syndrome, which includes insulin resistance, hyper-
tension, dyslipidemia, and a procoagulant state. While emerging evidence suggests that
impaired FBG (FBG_110 mg/dl) may accelerate atherosclerosis, we sought to evaluate
the independent impact of FBG in the upper normal range (<110 mg/dl) as a risk factor
for subclinical coronary atherosclerosis assessed by coronary artery calcification (CAC)
in an asymptomatic non-diabetic population.
Methods : We studied 531 consecutive asymptomatic, non-diabetic males (46±7 yrs;
range 29-65 yrs) with FBG<110 mg/dl in the study who presented for electron-beam
computed tomography (EBCT) between 1999 and 2002 in Sao Paulo, Brazil. The popula-
tion was divided into 2 categories; highest quartile of FBG (>85 mg/dl, n=119) and the
lowest three quartiles (n=412).
Results:Individuals in the highest quartile of FBG were more likely to have higher body
mass index (28±4 vs. 26±3, p<0.0001), waist to hip ratio (0.99±0.06 vs. 0.93±0.06,
p=0.01), triglycerides (410±116 vs. 180±92, p=0.05) and systolic blood pressure (131±14
vs.121±13, p<0.0001), where as no significant difference was observed in high density
lipoprotein, low density lipoprotein and total cholesterol levels respectively. Overall
median, 75th percentile and 90th percentile CAC scores were: 3, 24 and 156 among indi-
viduals with highest FBG quartile compared to 0, 6 and 56 among patients with lowest
three quartiles (p<0.05). After adjusting for potential cofounders, the odds ratio for any
calcification (CAC>0) with FBG>85 mg/dl was 2.5 (95% CI=1.1-5.4, p=0.02) and 1.8 (1.1-
3.2, p=0.01) for >75th percentile CAC, respectively
Conclusions: FBG in the upper normal range (>85 mg/dl) appears to be an important
independent predictor of presence and severity of CAC in non-diabetic apparently
healthy young/middle aged men.
1028-172 Increased Urinary 8-Iso-Prostaglandin F2alpha 
Excretion Predict Cardiac Events in Patients With Type 
2 Diabetes
Yusuke Nakagawa, Yoshiyuki Kijima, Akira Nishibe, Nobuyuki Ogasawara, Tamayo 
Ishiko, Megumi Kunishige, Takeshi Hata, Higashiosaka City General Hospital, 
Higashiosaka, Japan
Background: Increased oxidant stress may play a key role in the etiology of diabetic car-
diovascular complications. We hypothesized that increased production of 8-iso-prostag-
landin F2alpha (8-iso-PGF2alpha), a marker for in vivo oxidant stress, predicts future
cardiac events in type 2 diabetic patients.
Methods: We studied 148 patients aged 30-85 (62±10) with type 2 diabetes. Baseline
level of urinary 8-iso-PGF2alpha excretions were measured and the patients were fol-
lowed up for a mean period of 1380 days. Cardiac events were defined as hospitalization
for acute myocardial infarction, unstable angina, revascularization, and worsening heart
failure.
Results: One hundred thirty-nine patients completed the follow-up, while 2 died of non-
cardiac causes. Of the remaining 137 patients, cardiac events were occurred in 16. Uri-
nary 8-iso-PGF2alpha excretion above the median value of 287.5 pg/mg creatinine was
Multivariate association between Lp-PLA2 and CRP with cardiovascular events at 
follow-up.
Endpoint Lp-PLA2
HR (95% confidence 
intervals)
logCRP
HR(95% confidence 
intervals)
Cardiac Death + AMI 1.31 (0.94, 1.81) 1.14 (0.73, 1.79)
Cardiac Death + AMI + Stroke 1.33 (1.02, 1.74) 1.26 (0.86,1.84)
Cardiac Death + AMI + 
Revascularization
1.25 (0.96, 1.64) 1.20 (0.88, 1.64)
Cardiac Death + AMI + 
Revascularization + Stroke
1.29 (1.02, 1.63) 1.26 (0.95, 1.67)
All-Cause Death + AMI 1.30 (1.01, 1.67) 1.35 (0.96, 1.89)
All-Cause Death + AMI + Stroke 1.32 (1.06, 1.65) 1.39 (1.03, 1.89)
All-Cause Death + AMI + 
Revascularization
1.28 (1.02, 1.61) 1.30 (0.99, 1.70)
All-Cause Death + AMI + 
Revascularization + Stroke
1.31 (1.06, 1.60) 1.34 (1.04, 1.72)
